Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2

NCT01996267 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

437

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HER2 Positive

Interventions

DRUG: PTC+Pertuzumab
DRUG: FEC-T+Pertuzumab

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]
[object Object]